NCT07550634Not yet recruitingPhase 1
A Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of MDR-001 Tablets in Patients With Mild and Moderate Hepatic Impairment and Matched Participants With Normal Hepatic Function
MindRank AI Ltd1 site in 1 country32 target enrollmentStarted: June 1, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Primary pharmacokinetic (PK) parameters of MDR-001
Study Overview
Brief Summary
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment and to matched healthy controls. The study aims to evaluate the pharmacokinetics and safety of MDR-001 in these populations. Primary pharmacokinetic endpoints include AUC and Cmax; safety endpoints include adverse events, vital signs, ECG, and laboratory assessments.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Voluntary signed informed consent before any study-related activities, and ability to understand the study procedures and methods, and willingness to strictly comply with the protocol to complete the study.
- •Participants (including their partners) must have no pregnancy plan and voluntarily take effective contraceptive measures from screening until 6 months after study drug administration.
- •Age 18 to 70 years (inclusive), male or female.
- •Male body weight ≥50 kg, female body weight ≥45 kg; body mass index (BMI) between 18 and 32 kg/m² (inclusive).
- •Estimated glomerular filtration rate (eGFR, calculated by CKD-EPI formula) ≥60 mL/min/1.73m².
- •Additional criteria for participants with hepatic impairment:
- •Chronic liver injury caused by primary liver disease (e.g., hepatitis B, hepatitis C, autoimmune hepatitis, alcoholic liver disease, etc.).
- •Child-Pugh grade A or B (see Appendix 1); recent liver function and complications stable, no significant deterioration (e.g., abdominal pain, increased ascites, nausea, vomiting, anorexia, fever, or worsening of liver-related laboratory results).
- •Stable medication regimen (including type, dose, or frequency) for the treatment of hepatic impairment, complications, or other concomitant diseases for at least 14 days before study drug administration, with no need for adjustment (diuretics and insulin, etc., excepted); or not taking any such medications.
Exclusion Criteria
- •Allergic constitution, including severe drug allergy or history of drug anaphylaxis; known allergy to the study drug or any of its components.
- •Screening ECG showing QTcF >450 msec (males) or >470 msec (females) (Fridericia correction); personal or family history of long QT syndrome; family history (parents, children, siblings) of sudden death before age 40; and/or personal history of unexplained syncope within 1 year before screening.
- •Dysphagia or any gastrointestinal disease affecting drug absorption, including frequent nausea or vomiting from any cause; active peptic ulcer; constipation.
- •Within 6 months before screening: severe gastrointestinal disease (e.g., active ulcer) or gastrointestinal surgery (except appendectomy, cholecystectomy, or other endoscopic procedures judged not to significantly affect gastrointestinal motility); clinically significant gastric emptying abnormality (e.g., pyloric obstruction, gastroparesis).
- •Any symptomatic bacterial, viral, parasitic, or fungal infection requiring treatment at screening (except hepatitis B or C); history of serious active infection within 1 month before screening.
- •Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or genetic disorders predisposing to medullary thyroid carcinoma.
- •Blood donation or blood loss ≥400 mL within 3 months before screening, or planned blood donation during the study or within 1 month after study completion.
- •Use of another investigational drug within 3 months before screening, or planned participation in another clinical study during this study.
- •Use of CYP3A4 inhibitors/inducers or P-gp inhibitors within 14 days before first dose, or planned use during the study.
- •Pregnant or breastfeeding women, or positive pregnancy test.
- •History of depression or other serious mental disorders (e.g., schizophrenia, bipolar disorder, or other severe mood or anxiety disorders); history of suicidal ideation or suicidal behavior.
- •Any other reason judged by the investigator as unsuitable for enrollment.
Arms & Interventions
Cohort C: Matched normal hepatic function
Experimental
Intervention: MDR-001 (Drug)
Cohort A: Mild hepatic impairment
Experimental
Intervention: MDR-001 (Drug)
Cohort B: Moderate hepatic impairment
Experimental
Intervention: MDR-001 (Drug)
Outcomes
Primary Outcomes
Primary pharmacokinetic (PK) parameters of MDR-001
Time Frame: Baseline (Day 1 pre-dose) and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose on Day 1 (single dose).
Maximum observed plasma concentration (Cmax) of MDR-001 following a single oral dose.
Secondary Outcomes
- Secondary pharmacokinetic parameters(Baseline (Day 1 pre-dose) and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose on Day 1 (single dose).)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment PatientsNCT07347808Vincentage Pharma Co., Ltd16
Not yet recruiting
Phase 1
JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFRSolid CancersNCT07510841Biotech Pharmaceutical Co., Ltd.228
Recruiting
Phase 1
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese ParticipantsHealthy Volunteers (HV)NCT07525947Jade Biosciences, Inc.40
Completed
Phase 1
一项在超重或肥胖受试者中评价口服小分子 MDR-001 片治疗 12 周的有效性和安全性的随机、双盲、安慰剂对照的 Ib 期临床研究肥胖CTR20251042杭州德睿智药科技有限公司
Not yet recruiting
Phase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese SubjectsDeliriumNCT07422142Kunming Pharmaceuticals, Inc.54